Cybeats Technologies Corp (OTCMKTS:CYBCF) Stock Soars 47% After License Agreement with Starfish Medical

On Monday, Cybeats Technologies Corp (OTCMKTS:CYBCF) was in focus after the company announced that it had inked a licensing agreement for SBOM Studio with StarFish Medical. StarFish is a leader in the North American full-service medical devices space. It was a major new announcement from the company and one that could bring the Cybeats into sharp focus among investors this week.

Cybeats Announces License Agreement with Starfish Medical, Canada’s Largest Contract Medical Device Design, Development and Contract Manufacturer

The Chief Executive Officer of the company Bob Lyle spoke about the latest development as well. He noted that the interest expressed by a leading medical devices company was an indication that there was rising demand for the SBOM management solutions which are offered by the company.

He went on to note that these solutions help with cybersecurity-related risk management and also comply with the newly launched requirements from the United States Food and Drug Administration for SBOMs.

The SBOM studio from Cybeats is known for delivering full-service supply chain intelligence technology which would help StarFish to effectively manage its Software Bill of Materials (SBOM). Additionally, these solutions would also help the company in assessing all the cybersecurity risks that may endanger the variety of medical device projects that it works on.